Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation

Edmundo Rosales Mayor (Barcelona, Spain), Edmundo Rosales Mayor, Victoria Alcaraz Serrano, Isabel Amara-Elori, Beatriz Montull, Alexandra Gimeno, Gerard Muñoz, Montserrat Vendrell, Rosa María Girón, Rosario Menendez, Polverino Eva, Antoni Torres

Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Session: Possible phenotypes of bronchiectasis and exacerbations
Session type: Poster Discussion
Number: 1548
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Edmundo Rosales Mayor (Barcelona, Spain), Edmundo Rosales Mayor, Victoria Alcaraz Serrano, Isabel Amara-Elori, Beatriz Montull, Alexandra Gimeno, Gerard Muñoz, Montserrat Vendrell, Rosa María Girón, Rosario Menendez, Polverino Eva, Antoni Torres. Chronic inhaled corticosteroids in patients with bronchiectasis who suffer an exacerbation. Eur Respir J 2016; 48: Suppl. 60, 1548

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013


Exacerbations and inhaled corticosteroids in bronchiectasis patients
Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis
Year: 2019

Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004



Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003



Predictors of exacerbations in patients with bronchiectasis
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007



The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020


Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011



Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016



Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010



Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020
Year: 2020



Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009



Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016


Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006



Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry.
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020